MEDVi Weight Loss review

Our take: real medicines, sold by a marketing company with a paper trail

Most products reviewed on this site have a weak ingredient and a strong sales page. Medvi is the opposite problem. The molecules it sells — semaglutide and tirzepatide — are among the best-evidenced weight-loss treatments ever tested, with trial results no supplement comes close to. The difficulty is everything wrapped around them.

Medvi (styled MEDVi) is not a clinic, a pharmacy or a drug maker. It is a consumer-facing storefront: it runs the website and the advertising, while an outsourced clinician network decides who gets a prescription and outside pharmacies make and ship the medicine. Its sign-up page leads with compounded versions of the drugs, which the FDA does not review for safety, effectiveness or quality, and it also sells a daily "GLP-1 tablet" for which we could find no published human evidence at all.

The record around the company is unusually long for one founded in 2024: an FDA warning letter addressed to MEDVi, LLC in February 2026, which the company says concerned an affiliate's website; reporting on deepfaked before-and-after photographs and AI-generated doctors in its advertising; a federal class action over oral GLP-1 tablets whose lead plaintiff bought them through Medvi; and an F rating from the Better Business Bureau. None of that is a finding that the medicine you would receive is faulty. All of it is a reason to read the small print more carefully than usual.

Our view: if you and a clinician have decided a GLP-1 is right for you, there are now cleaner routes to the FDA-approved versions at similar prices. The Wegovy pill bought direct from its manufacturer costs the same $299 a month at maintenance as Medvi's compounded injection refill. Medvi's best case is convenience for someone with no prescriber of their own. We would not buy its tablets at any price.

This is a desk review. Nobody at SharpAndLean signed up, completed Medvi's intake or took medication from it. Prices, policies and disclaimers were read from Medvi's own pages on 25 September 2026; everything else is traced to a regulator, a court filing, a trial or named reporting, listed in the references below.

What Medvi is, and what it is not

MEDVi, LLC was incorporated in Delaware in April 2024 and gives an address in Newark, Delaware. Its founder, Matthew Gallagher, has said he launched it from his Los Angeles home with about $20,000 and a stack of AI tools. In April 2026 the New York Times and Forbes reported it was on course for $1.8 billion in sales with two employees — Gallagher and his brother Elliot, whom the BBB lists as chief operating officer. The site now claims more than 500,000 patients.

Two people cannot prescribe to half a million, and they do not. Medvi's own footer sets out the structure. Its online assessment, it says, does not create a doctor-patient relationship. Prescribing is done by clinicians from OpenLoop Health and affiliated professional corporations, who decide whether to prescribe. The medicine is dispensed by partner pharmacies it names as Triad Rx in Alabama, RedRock Pharmacy in Utah and Beaker Pharmacy & Compounding in Texas. Its terms state that Medvi does not act as a pharmacy and does not make compounded medicines.

That arrangement is legal and common in telehealth. It does mean the company whose name is on the website is responsible for the marketing rather than the medicine — and when something goes wrong with a dose or a delivery, you may be dealing with three organisations instead of one.

One sequencing detail is worth knowing before you start. The footer says the OpenLoop clinician meets you after checkout: you pay first and are assessed second. Medvi's refund policy promises a full refund if a clinician disqualifies you for a medical reason.

What is on the menu, and what it costs

These are the prices on Medvi's GLP-1 sign-up page on 25 September 2026, under a banner still advertising a summer sale:

• Compounded GLP-1 injections — from $149 for the first month. The page's FAQ says the semaglutide programme then refills at $299 a month, covering the prescriber, the medication and shipping, with no separate membership fee.
• Compounded GLP-1 tablets — from $249, one dissolvable tablet a day. The page does not say which molecule they contain.
• Wegovy pill, Wegovy injection and Zepbound injection — a $99 monthly membership plus the cost of the medication, which the page does not state.

The vial pictured at the top of this page is Medvi's own render for its compounded injections, taken from that sign-up page. It carries no brand name — the FDA's warning letter objected to earlier product images labelled MEDVi, because they implied Medvi made the drug — and Medvi's footer says the medication you receive may look different from what its website shows.

We could not find a price for compounded tirzepatide injections on the pages we read, although the FDA's warning letter shows Medvi-branded compounded tirzepatide was being marketed at the end of 2025. Ask before you pay.

At the compounded semaglutide prices, a first year costs $149 plus eleven refills at $299 — about $3,438. Two other details sit in the small print. The "no hidden fees" promise applies to the compounded plans; the branded route carries a membership on top of the drug. And the "free" dietitian visits are footnoted as subject to insurance and copay eligibility, which is not quite the same thing as free.

The medicines work — the question is which version you get

The branded drugs have some of the best evidence in medicine

In STEP 1, weekly semaglutide 2.4 mg — the drug sold as Wegovy — produced a mean weight loss of 14.9 per cent over 68 weeks, against 2.4 per cent on placebo. In SURMOUNT-1, tirzepatide 15 mg, sold as Zepbound, produced 20.9 per cent over 72 weeks. The newer Wegovy pill, oral semaglutide 25 mg, produced 13.6 per cent over 64 weeks against 2.2 per cent on placebo in the 307-person OASIS 4 trial, and was approved by the FDA in December 2025. Our GLP-1 explainer goes through these trials, and what happens when people stop.

Those are the products Medvi offers through its $99 membership route. If that is what you are prescribed, you are getting exactly what was tested.

Compounded injections are the same molecule, not the same product

What Medvi leads with is compounded semaglutide and tirzepatide: versions mixed by a pharmacy rather than made by Novo Nordisk or Eli Lilly. The FDA's position is that compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness or quality before they are sold. No compounded product has been through a trial; the STEP and SURMOUNT results belong to the branded drugs.

That is not the same as saying compounded injections do not work — plenty of people lose weight on them. It is saying the evidence stops at the molecule, and the quality of what arrives depends on a pharmacy you did not choose. As of 31 May 2026 the FDA had received 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, and it describes those figures as an undercount because many state-licensed pharmacies are not required to report. A recurring cause is dosing error: compounded vials are drawn up by hand with a syringe, and confusion between millilitres, units and milligrams has produced ten-fold overdoses. Branded pens are pre-set.

Medvi's disclaimer says its compounded medicines are made in "FDA-regulated facilities". It does not say which kind. Outsourcing facilities registered under section 503B of federal law work to federal manufacturing standards and are inspected by the FDA; ordinary compounding pharmacies operating under section 503A are overseen mainly by state pharmacy boards. Ask which your pharmacy is.

The tablets are the weakest thing on the menu

Semaglutide and tirzepatide are peptides — chains of amino acids that the gut digests like any other protein. The Wegovy pill works only because semaglutide is co-formulated with an absorption enhancer called SNAC, which protects it in the stomach and carries it through the stomach lining. Even with SNAC, roughly 1 per cent of an oral dose reaches the bloodstream, which is why the pill has to be taken on an empty stomach with a sip of water. A compounded tablet without that technology has no established route into the body, and we could find no published human study showing that compounded oral tirzepatide or compounded oral semaglutide reaches meaningful blood levels.

That gap is now in federal court. Day v. OpenLoop Health, filed in Delaware in November 2025, alleges that "oral tirzepatide" tablets sold through a network of telehealth storefronts cannot be absorbed and are effectively inert. It brings racketeering, fraud and consumer-protection claims against OpenLoop and Triad Rx — the same clinician network and one of the three pharmacies Medvi names. The lead plaintiff says he bought a one-month supply from medvi.org in October 2025 for $279.99. Medvi is not a defendant; the complaint describes it as one of many near-identical storefronts. These are allegations, and no court has found against the defendants.

Medvi's current page offers "GLP-1 tablets" from $249 without saying which molecule they contain. Our advice does not depend on the answer: we would not pay for a compounded GLP-1 tablet until someone publishes evidence that it is absorbed.

Side effects come with the molecule

Whichever version you receive, the side effects of the drug class apply. In the Wegovy injection trials, nausea affected 44 per cent of people, diarrhoea 30 per cent, vomiting 24 per cent and constipation 24 per cent, against 16, 16, 6 and 11 per cent on placebo. Pancreatitis and gallbladder disease are rarer but listed, and the drugs carry a boxed warning about thyroid C-cell tumours seen in rodents: they are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. They are not for use in pregnancy. Tirzepatide can make oral contraceptives less reliable, the drugs can cause low blood sugar alongside insulin or sulfonylureas, and anyone having an anaesthetic needs to tell the team they are on one.

An online questionnaire can only screen for what you tell it. If any of the above applies to you, it belongs in the intake — and in a conversation with a clinician who knows your history.

Medvi's own numbers, checked

The sign-up page makes three headline claims: that customers lose an average of 18 per cent of their body weight, that they lose six times more than with diet and exercise alone, and that 93 per cent kept the weight off for good. All three are footnoted as data from Medvi patients over their first six months. The homepage adds that the figures are self-reported: customers enter their weight on a questionnaire every three to four weeks.

The 18 per cent. The branded trials needed 68 to 72 weeks, with weight measured by trial staff, to reach 15 to 21 per cent. Medvi reports a comparable figure at six months, from weights customers typed in themselves. Self-reported averages also have a survivor problem: people who stall, have side effects or cancel tend to stop reporting, and drop out of the average. Without the number who started and the number still reporting, the figure cannot be checked.

Six times diet and exercise. A dataset of paying customers contains nobody on diet and exercise alone, so it cannot produce this comparison. The ratio does match STEP 1, where 14.9 per cent on branded semaglutide against 2.4 per cent on placebo is about six to one. That is a trial of Wegovy, not of Medvi's customers or of compounded product.

Ninety-three per cent kept it off for good. Six months of data cannot show that anyone kept weight off for good, and most people in their first six months are still on treatment. When STEP 1 participants stopped semaglutide, they regained a mean of 11.6 percentage points within a year — about two-thirds of what they had lost. Keeping the weight off on these drugs generally means staying on them, which is a cost question as much as a medical one.

Elsewhere the page promises to fix a broken metabolism. GLP-1 drugs act mainly on appetite and on how quickly the stomach empties. They do not repair anything, and the regain data shows the effect lasts about as long as the prescription.

The marketing record and the FDA letter

Before-and-after photographs that were not patients

In May 2025 Futurism reported that before-and-after pictures presented on Medvi's site as patients had been lifted from images circulating online for years, with the faces altered by AI. One "patient" was traced to a 2018 newspaper story about a man whose weight loss took place years before semaglutide was approved for weight loss; one advert showed an AI-generated Ozempic box with garbled lettering. The same report found a real physician who said he had nothing to do with the company and wanted his name taken off its sites. Medvi did not respond to Futurism at the time.

The site's footer now says some of its text, images and media may be generated or enhanced with AI, that people in its advertisements may be actors or models, and that testimonial images may use models to protect patient privacy. The descriptive text attached to several of the testimonial photographs on the sign-up page reads like generic stock-library captions rather than descriptions of patients.

Doctors who were not doctors

In April 2026, after a New York Times profile brought the company wide attention, reporters documented social-media accounts posing as physicians and running Medvi adverts. Medvi told Futurism it had recently become aware of adverts that appeared to feature AI-generated medical practitioners, and that it had changed its marketing rules to prohibit them.

The FDA warning letter

On 20 February 2026 the FDA's Office of Compounding Quality and Compliance sent a warning letter to MEDVi, LLC at the same Newark address printed on medvi.org. The agency had reviewed content at medvi.io in December 2025 and found Medvi-branded compounded semaglutide and tirzepatide misbranded on two grounds. Claims such as "Same active ingredient as Wegovy® and Ozempic®", it said, implied the compounded products were FDA-approved or equivalent to the approved drugs. And product images carrying the MEDVi name falsely suggested that Medvi was the compounder. It asked for a written response within 15 working days, including who actually made the drugs.

Gallagher told Futurism in April that the letter concerned medvi.io, an affiliate's website, and that his company had never received a letter from the FDA. We cannot settle that from the outside. The letter is addressed to MEDVi, LLC, and we found no published close-out letter.

Medvi was not singled out. On 3 March 2026 the FDA announced 30 more warning letters to telehealth companies for the same two practices, and in February it said it intended to restrict the GLP-1 ingredients used in unapproved compounded drugs. The regulatory ground under compounded GLP-1s is shifting, so anyone starting a course should ask what happens if their pharmacy can no longer supply it.

The New York Times profile

The Times profiled Medvi on 2 April 2026 as an example of a very large business run by a very small, AI-assisted team. After readers pointed out what it had left out, the paper updated the article and added an editor's note saying it should have mentioned the FDA letter and a pending class action accusing Medvi of breaking California's anti-spam law. Medvi's sign-up page displays the Times logo alongside Forbes, WebMD and others, under a heading that runs together publications that have covered the company and publications it has advertised in. A logo strip is not an endorsement.

Lawsuits, complaints and the refund policy

In court

• A California anti-spam class action, filed in March 2026 and pending, alleges Medvi benefited from commercial email that broke California law. This is the case the Times editor's note refers to.
• Day v. OpenLoop Health, the Delaware oral-tirzepatide complaint described above. Medvi is named as the storefront the plaintiff bought from, not as a defendant.
• Unsolicited text messages. The Delaware complaint records that in a 2025 federal case in Florida over unsolicited marketing texts, Medvi was served and did not appear.

All of these are allegations. We found no judgment against Medvi on the merits of any of them.

What customers say

On 25 September 2026 Medvi had a 4.3 rating across 14,833 reviews on Trustpilot, where it has claimed its profile and pays for a subscription. Two of the three most recent reviews on its summary page were marked as invited by the company — a normal practice, and one that tends to draw happier customers. Reviewers often praise the clinicians and support staff. The complaints that do appear are about delivery delays, double charges, confusing dose instructions and difficulty cancelling.

The Better Business Bureau rates Medvi F, citing 749 complaints and a failure to respond to 133 of them. The BBB itself cautions that complaint counts should be read against a company's size, and against 500,000 claimed patients the raw number is modest. The unanswered ones — nearly one complaint in five — are the more telling figure.

Cancelling: read this before you pay

Medvi's refund policy is strict, and parts of it are printed in capital letters.

• You can cancel at any time, by email or through the patient portal, but the request must arrive at least 72 hours before your next billing date or you will be charged for another cycle.
• On a monthly plan there is no refund for the month in which you cancel, or for any earlier month.
• A full refund is available only if you cancel within 72 hours of starting and have received no services, or if a clinician disqualifies you.
• On a plan billed two or more months at a time, you are refunded for months in which no medication shipped.
• Prescription medicine cannot be returned once dispensed.

The same policy says there is no guarantee of results. The sign-up page, meanwhile, advertises a "MEDVi guarantee" beside a money-back-guarantee icon, and according to screenshots filed in the Delaware complaint, the homepage in November 2025 promised weight loss or your money back. Whatever the marketing says, the refund policy is the document that governs your money. Put the 72-hour deadline in your calendar the day you sign up.

Medvi or going direct?

When the branded drugs were in shortage and cost well over $1,000 a month at list price, the case for compounded versions was easy to make. Both manufacturers now sell direct to people paying for themselves, and the gap has narrowed to almost nothing. On 25 September 2026:

• Wegovy pill, from NovoCare Pharmacy — $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg.
• Wegovy injection, from NovoCare Pharmacy — $199 a month for the first two fills at the starting doses for new patients until 31 December 2026, then $349 a month; $399 for the 7.2 mg high dose.
• Zepbound, from LillyDirect — $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5 to 15 mg if you refill within 45 days, rising to $499 to $699 if you do not.
• Medvi compounded semaglutide — $149 for the first month, then $299.

At maintenance, then, the FDA-approved Wegovy pill costs the same $299 a month as Medvi's compounded semaglutide injection, and the approved injection costs $50 more. The catch is that buying direct needs a prescription, and Medvi's price includes the prescriber. If you have a doctor willing to prescribe, the direct route gets you an approved product for about the same money. If you do not, Medvi's $99 membership is one way to get a prescription for the branded drugs — at a monthly total of roughly $250 to $550 depending on drug and dose, if the medication is priced at the manufacturers' self-pay rates. Medvi does not publish that medication cost, so ask for it in writing.

Medvi says all its prescriptions are cash-pay. If your insurance covers Wegovy or Zepbound, a copay through your own doctor may undercut every price on this page.

How we scored a service against supplement criteria

Our five criteria were written for products on a shelf, so each needs translating for a prescription service. We applied them to what Medvi sells as a package — the prescription, the medicine and the terms — and gave the compounded injections the most weight, because they are what the sign-up page leads with.

• Evidence, 5 out of 10. The molecules are A-grade and the branded options are exactly what was tested. The compounded products have no trials, the tablets have no human evidence, and the headline results are self-reported.
• Dose, 5. Clinicians can titrate injections to the studied doses, and the semaglutide refill price is flat. But compounded vials are measured by hand, and the tablets have no studied dose to hit.
• Transparency, 3. Credit for naming the clinician network, the pharmacies and the not-FDA-approved status. Marked down for the FDA letter, an unnamed tablet molecule, an unstated branded medication cost and a guarantee the refund policy disclaims.
• Value, 4. The approved Wegovy pill costs the same at maintenance bought direct. Medvi's price includes a prescriber; the discount for accepting an unapproved product has all but gone.
• Safety, 4. Well-characterised class effects, plus unreviewed compounding quality, hand-measured doses and tablets alleged in court to be inert.

The result, 4.2 out of 10, is not a score for semaglutide or tirzepatide. It is a score for buying them this way.

Sources and shopping: what to check before signing up

If you decide to use Medvi, these are the questions worth asking — in writing, before you pay:

• Which exact drug, strength and form will I receive, and is it compounded or FDA-approved?
• Which pharmacy will fill it, and is it a 503B outsourcing facility or a 503A pharmacy?
• What will each later month cost at each dose, including any membership?
• For a compounded vial: in what units is my dose measured, and who shows me how to draw it up?
• Who do I contact about side effects out of hours, and is that person a clinician?
• What is my billing date, and how do I cancel before the 72-hour cut-off?

Before any of that, check whether your own doctor or insurer can get you an approved GLP-1. And decline the tablets.

We have no commercial relationship with Medvi, and this page carries no buy link. Every figure above is traced to a source in the references below.